Table 3.

AEs leading to permanent discontinuation and AESIs

	Feladilimab mg/tremelimumab mg
Preferred term, n (%)	8/75 (N = 1)	24/75 (N = 1)	8/225 (N = 5)	80/75 (N = 3)	24/225 (N = 16)	Total (N = 26)
AEs leading to permanent discontinuation	0	0	1 (20)	0	3 (19)	4 (15)
Colitis	0	0	0	0	1 (6)	1 (4)
Diarrhea	0	0	0	0	1 (6)	1 (4)
Fatigue	0	0	0	0	1 (6)	1 (4)
Acute kidney injury	0	0	0	0	1 (6)	1 (4)
Dyspnea	0	0	1 (20)	0	0	1 (4)
AESIs	0	0	2 (40)	0	7 (44)	9 (25)
Colitis	0	0	1 (20)	0	1 (6)	2 (8)
Endocrinopathies	0	0	0	0	2 (13)	2 (8)
Hepatitis	0	0	1 (20)	0	0	1 (4)
Nephritis and renal function	0	0	0	0	2 (13)	2 (8)
Other immune-mediated AEs	0	0	0	0	1 (6)	1 (4)
Skin adverse reactions	0	0	2 (40)	0	3 (19)	5 (19)

Individual patients could experience ≥ 1 listed AE

AE adverse event, AESI adverse event of special interest